Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Wild-Type ATTR Cardiac Amyloidosis

Cardiovascular

Wild-Type ATTR Cardiac Amyloidosis (SSA) Clinical Trials

Also called ATTRwt, Senile systemic amyloidosis, SSA, Wild-type transthyretin amyloidosis, Age-related ATTR, ATTR-CM wild-type, Non-hereditary ATTR, ATTR-CM, Transthyretin amyloid cardiomyopathy

Wild-type ATTR cardiac amyloidosis is a spontaneous age-related disease where normal transthyretin protein becomes unstable and misfolds into amyloid fibrils that accumulate in cardiac tissue. Unlike hereditary ATTR, no genetic mutation causes the disease. The condition creates restrictive cardiomyopathy with preserved ejection fraction, producing prominent right-sided heart failure symptoms including lower extremity edema and fluid retention.

In plain words, wild-type ATTR cardiac amyloidosis happens when the normal protein transthyretin folds the wrong way with age and builds up in the heart. Over time this stiffens the heart and leads to heart failure, and it is not caused by an inherited gene change.

Get an email when new Wild-Type ATTR Cardiac Amyloidosis trials open or the FDA decides. Get alerts

Wild-Type ATTR Cardiac Amyloidosis

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 8 studies with no phase, like observational studies, and 1 phase 4 study following medicines after approval.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines3

Amvuttra · Attruby · Vyndamax

Wild-Type ATTR Cardiac Amyloidosis has 3 FDA-approved medicines, 9 open or active clinical trials (9 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Wild-Type ATTR Cardiac Amyloidosis

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Wild-Type ATTR Cardiac Amyloidosis

Cardiac manifestations include increased wall thickness, restrictive filling patterns, and frequent atrial fibrillation (affecting 40-60% of patients). Importantly, carpal tunnel syndrome often appears about 9 years before the heart disease is diagnosed, providing a potential window for early diagnosis. The disease predominantly affects very elderly males, yet remains profoundly underdiagnosed as symptoms are often attributed to other common conditions.

Keep reading about Wild-Type ATTR Cardiac Amyloidosis

Most people are diagnosed without a biopsy. Once blood and urine tests (serum free light chains and immunofixation) rule out AL amyloidosis, a PYP, DPD or HMDP bone scan showing grade 2 or 3 heart uptake confirms ATTR, and TTR gene sequencing then shows whether it is wild-type or hereditary. A biopsy is needed when the light chain tests are abnormal or the scan is unclear. Recent studies suggest wild-type ATTR may account for 5-10% of heart failure cases in elderly populations.

What are the symptoms of Wild-Type ATTR Cardiac Amyloidosis?

These are common symptoms of Wild-Type ATTR Cardiac Amyloidosis, and how strong they are varies from person to person.

  • Shortness of breath and exercise intolerance
  • Leg and ankle swelling
  • Fatigue and weakness
  • Irregular heartbeat or palpitations
  • Fainting or near-fainting from conduction abnormalities
  • Carpal tunnel syndrome (often about 9 years before the heart disease is diagnosed)

Who gets Wild-Type ATTR Cardiac Amyloidosis?

Wild-type ATTR predominantly affects males over 60 years old, with mean age of symptom onset around 80 years. Male predominance ranges from 75 to 91% in clinical populations. Female cases are increasingly recognized but remain less common.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Wild-Type ATTR Cardiac Amyloidosis?

There are currently 3 FDA-approved medications for Wild-Type ATTR Cardiac Amyloidosis.

vutrisiran
Alnylam Pharmaceuticals
Official site
acoramidis
BridgeBio Pharma
Search
tafamidis

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Which new Wild-Type ATTR Cardiac Amyloidosis medicines are in trials?

Investigational medicines Trial Friend tracks for Wild-Type ATTR Cardiac Amyloidosis, with trial results, safety findings and where each one stands.

How to get help paying for Wild-Type ATTR Cardiac Amyloidosis treatment

Charity funds and drugmaker programs for Wild-Type ATTR Cardiac Amyloidosis, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · NORD RareCare
    Amyloidosis Medical Assistance fund
    Waitlist

    Pays for: Medical and medication costs.

    The foundation says: “Temporarily Waitlisting”
  • From a charity · NORD RareCare
    Amyloidosis Premium Copay Assistance fund
    Waitlist

    Pays for: Insurance premiums and copays.

    The foundation says: “Temporarily Waitlisting”
  • From a charity · The Assistance Fund
    Amyloidosis fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 16, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Wild-Type ATTR Cardiac Amyloidosis, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Wild-Type ATTR Cardiac Amyloidosis

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Wild-Type ATTR Cardiac Amyloidosis resources

Reputable organizations and medical references for learning more about Wild-Type ATTR Cardiac Amyloidosis, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Wild-Type ATTR Cardiac Amyloidosis

Use this Wild-Type ATTR Cardiac Amyloidosis clinical trial finder to see the 9 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. Of these, 1 tests a treatment and 8 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map, the pipeline timeline or the medication checker.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

9 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 4Recently updatedNCT07298044

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Intervention: Acoramidis

Sponsor: Bayer

Transthyretin (TTR) is a protein made by the liver that helps transport thyroid hormone and vitamin A in the blood. In some people, this protein breaks down and forms harmful clumps called amyloid. TTR amyloid gets deposited in the heart wall and stops it from pumping blood prope...

Ages 18 Years to 90 Years
Started Feb 2026Updated 1 week agoEst. Sep 2027 (~9 months)
RecruitingObservational study, no treatment givenRecently updatedNCT07235462

A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting

Intervention: Acoramidis (356 mg film-coated tablets)

Sponsor: Bayer

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up as amyloid fibrils in the heart muscle. This buildup causes the heart to become stiff, leading to restrictive cardiomyopath...

Ages 18 Years+
Started Oct 2025Updated 1 month agoEst. Apr 2028 (~1y 5m)
RecruitingObservational study, no treatment givenRecently updatedNCT06465810

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Intervention: Treatment of transthyretin (ATTR) amyloidosis in observational study setting

Sponsor: AstraZeneca · ICON plc

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidos...

Ages 18 Years to 130 Years
Started Jun 2024Updated 1 month agoEst. Dec 2031 (~5y 1m)
RecruitingObservational study, no treatment givenRecently updatedNCT07791160

Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy

Intervention: Acoramidis

Sponsor: Bayer

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart disease caused by the buildup of an abnormal protein, called transthyretin (TTR), in the heart. This buildup can make it harder for the heart to pump blood and may lead to worsening symptoms over time. Acoramid...

Ages 18 Years+1 location
Started Sep 2026Updated 2 months agoEst. Dec 2028 (~2y 1m)
RecruitingObservational study, no treatment givenUpdated a few months agoNCT07766135

Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis

Sponsor: University of Messina

Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive infiltrative cardiomyopathy caused by the deposition of misfolded transthyretin protein within the myocardium. Current disease staging and follow-up strategies mainly rely on cardiac biomarkers and renal function; howev...

Ages 18 Years+1 location
Started Jan 2026Updated 3 months agoEst. Jan 2028 (~1y 2m)
Find Wild-Type ATTR Cardiac Amyloidosis trials near you, ranked by distance →
Active trial locations29 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+21 more

Trial Pipeline

Sep 2023 to Nov 2031
2024
2026
2028
2030
now
Phase 4
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Wild-Type ATTR Cardiac Amyloidosis trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Wild-Type ATTR Cardiac Amyloidosis foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Wild-Type ATTR Cardiac Amyloidosis patient communities

Facebook groups, Reddit communities and YouTube channels where Wild-Type ATTR Cardiac Amyloidosis patients, caregivers and advocacy groups talk.

Companies developing Wild-Type ATTR Cardiac Amyloidosis treatments

Drugmakers that list Wild-Type ATTR Cardiac Amyloidosis in their rare disease portfolio, 6 in all.

Questions people ask about Wild-Type ATTR Cardiac Amyloidosis